Early Response To Neoadjuvant Chemotherapy Can Help Predict Long-Term Survival In Patients With Cervical Cancer

Xiong Li,Kecheng Huang,Qinghua Zhang,Jian Shen,Hang Zhou,Runfeng Yang,Lin Wang,Jiong Liu,Jincheng Zhang,Haiying Sun,Yao Jia,Xiaofang Du,Haoran Wang,Song Deng,Ting Ding,Jingjing Jiang,Yunping Lu,Shuang Li,Shixuan Wang,Ding Ma

DOI: https://doi.org/10.18632/oncotarget.11460

2016-01-01

Oncotarget

Abstract:It is still controversial whether cervical cancer patients with clinical responses after neoadjuvant chemotherapy (NACT) have a better long-term survival or not. This study was designed to investigate the effect of the clinical response on the disease-free survival (DFS) of cervical cancer patients undergoing NACT. A total of 853 patients from a retrospective study were used to evaluate whether the clinical response was an indicator for the long-term response, and 493 patients from a prospective cohort study were used for further evaluation. The survival difference was detected by log-rank test, univariate and multivariate Cox regression and a pooled analysis. The log-rank test revealed that compared with non-responders, the DFS of responders was significantly higher in the retrospective data (P = 0.007). Univariate Cox regression showed that the clinical response was an indicator of long-term survival in the retrospective study (HR 1.83, 95% CI 1.18-2.85, P = 0.007). In a multivariate Cox model, the clinical response was still retained as an independent significant prognostic factor in the retrospective study (HR 1.59, 95% CI 1.01-2.50, P = 0.046). The result was also validated in the prospective data with similar results. These findings implied that the clinical response can be regarded as an independent predictor of DFS.